Antrafenine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317196

CAS#: 55300-30-6 (HCl)

Description: Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen. It is not widely used as it has largely been replaced by newer drugs.


Chemical Structure

img
Antrafenine HCl
CAS# 55300-30-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 317196
Name: Antrafenine HCl
CAS#: 55300-30-6 (HCl)
Chemical Formula: C30H28Cl2F6N4O2
Exact Mass: 588.196
Molecular Weight: 661.4704
Elemental Analysis: C, 54.47; H, 4.27; Cl, 10.72; F, 17.23; N, 8.47; O, 4.84

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-03-08. Prices are subject to change without notice.

Antrafenine HCl is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, SDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Related CAS #: 55300-29-3 (free base)   55300-30-6 (HCl)    

Synonym: Antrafenine HCl, SL 73-033, SL-73-033; SL73-033; SL 73033, SL-73033; SL73033; Stakan, Stakane; Antrafenine hydrochloride

IUPAC/Chemical Name: 2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl 2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate dihydrochloride

InChi Key: GEZLWXYIFNEJBC-UHFFFAOYSA-N

InChi Code: InChI=1S/C30H26F6N4O2.2ClH/c31-29(32,33)20-4-3-5-22(18-20)40-14-12-39(13-15-40)16-17-42-28(41)24-6-1-2-7-25(24)38-26-10-11-37-27-19-21(30(34,35)36)8-9-23(26)27;;/h1-11,18-19H,12-17H2,(H,37,38);2*1H

SMILES Code: O=C(OCCN1CCN(C2=CC=CC(C(F)(F)F)=C2)CC1)C3=CC=CC=C3NC4=CC=NC5=CC(C(F)(F)F)=CC=C45.[H]Cl.[H]Cl

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 661.4704 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wang Y, Law WK, Hu JS, Lin HQ, Ip TM, Wan DC. Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening. J Chem Inf Model. 2014 Nov 24;54(11):3046-50. doi: 10.1021/ci500503b. Epub 2014 Nov 4. PubMed PMID: 25360897.

2: Normand M, Bergua D, Bouvet JP, Cayotte JL, Gottis M. [Correlation of the cause and composition of renal calculi. Value of morphologic and infrared analysis]. Ann Biol Clin (Paris). 1989;47(1):29-34. Review. French. PubMed PMID: 2648901.

3: Moesch C, Rince M, Raby C, Leroux-Robert C. [Identification of a metabolite of floctafenine in urinary calculi]. Ann Biol Clin (Paris). 1987;45(5):546-50. French. PubMed PMID: 2892454.

4: Daudon M, Moesch C, Marty L, Normand M, Rince M, Leroux-Robert C, Reveillaud RJ. [Antrafenine, urinary calculi and crystalluria]. Therapie. 1986 Nov-Dec;41(6):499-504. French. PubMed PMID: 3810546.

5: Cheymol G, Biour M, Bruneel M, Albengres E, Hamel JD. [Evaluation of a national prospective survey on the undesirable effects of glafenine, antrafenine and floctafenine]. Therapie. 1985 Jan-Feb;40(1):45-50. French. PubMed PMID: 2860731.

6: Caccia S, Conti I, Notarnicola A. In-vivo metabolism in the rat and mouse of antrafenine to 1-m-trifluoromethylphenylpiperazine. J Pharm Pharmacol. 1985 Jan;37(1):75-7. PubMed PMID: 2858538.

7: Hensby CN, Maloubier A, Civier A, Shroot B, Ortonne JP. A model for studying the anti-prostaglandin activity of drugs in human skin. Br J Dermatol. 1984 Jul;111 Suppl 27:147-51. PubMed PMID: 6743546.

8: Dunn CJ, Prouteau M, Delahaye M, Purcell T, Branceni D. Antrafenine: anti-inflammatory activity with respect to oedema and leucocyte infiltration in the rat. Agents Actions. 1984 Feb;14(2):296-9. PubMed PMID: 6608864.

9: Caccia S, Notarnicola A, Fong MH, Benfenati E. Identification and quantitation of 1-arylpiperazines, metabolites resulting from side-chain cleavage of (4-substituted aryl-1-piperazinyl)alkyl heterocyclic derivatives in rat plasma and brain. J Chromatogr. 1984 Jan 20;283:211-21. PubMed PMID: 6707118.

10: Nicot G, Merle L, Coquelin JP, Valette JP, Lachatre G. [Proteins and urinary enzymes following administration of antrafenine in healthy volunteers]. Therapie. 1983 Jul-Aug;38(4):379-86. French. PubMed PMID: 6648882.